Abstract

BackgroundCancer of unknown primary (CUP) is usually treated with nonselective and empirical chemotherapy; however, its prognosis is generally poor, with a median survival of less than a year. Thus, clinicians eagerly await the development of more effective treatment strategies. In recent years, advances in next-generation sequencing (NGS) have made it possible to analyze comprehensively the genome of individual cancers. NGS has identified many genomic alterations, some of which are potential molecular targets of specific agents. We report a case of CUP that was successfully treated with targeted therapy directed by the genomic data obtained from an NGS-based multiplex assay.Case presentationA 52-year-old Asian woman with right hip joint pain underwent fluorodeoxyglucose-positron emission tomography/computed tomography, which showed multiple metastatic tumors in her right hip joint, thyroid gland, lung, and vertebrae. Brain magnetic resonance imaging showed multiple cerebral metastases. Additional tests, including pathology examination and conventional epidermal growth factor receptor (EGFR) gene mutation analysis (single-strand conformation polymorphism assay), could not identify the primary origin of the tumors, so the patient was diagnosed with CUP. After empirical chemotherapy for CUP, an NGS-based multiplex assay performed using a resected specimen of thyroid tumor detected the EGFR mutation c.2573 T > G p.Leu858Arg (L858R). Her treatment was changed to erlotinib, an EGFR tyrosine-kinase inhibiter, which dramatically shrank the tumors and decreased her serum carcinoembryonic antigen level. She achieved long-term disease control and survived for 2 years and 9 months from the first diagnosis.ConclusionThis case might support the strategy that NGS-based multiplex assays could identify actionable molecular targets for individual patients with CUP.

Highlights

  • Cancer of unknown primary (CUP) is usually treated with nonselective and empirical chemotherapy; its prognosis is generally poor, with a median survival of less than a year

  • This case might support the strategy that next-generation sequencing (NGS)-based multiplex assays could identify actionable molecular targets for individual patients with CUP

  • With the recent advance of next-generation sequencing (NGS), it has become feasible in daily clinical practice to select the potentially effective therapy for a patient based on comprehensive genetic analysis of his or her individual cancer [3,4,5]

Read more

Summary

Introduction

Cancer of unknown primary (CUP) is usually treated with nonselective and empirical chemotherapy; its prognosis is generally poor, with a median survival of less than a year. Conclusion: This case might support the strategy that NGS-based multiplex assays could identify actionable molecular targets for individual patients with CUP. With the recent advance of next-generation sequencing (NGS), it has become feasible in daily clinical practice to select the potentially effective therapy for a patient based on comprehensive genetic analysis of his or her individual cancer [3,4,5].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call